US senator says diabetes and weight-loss drug changed his life, here’s why

A U.S. senator recently shared his life-changing experience with a GLP-1 drug called Mounjaro (tirzepatide) in a New York Times op-ed on April 8. Sen. John Fetterman, D-Pa., who was prescribed the medication in July 2025, initially started taking it for his heart health as a stroke survivor. However, he was pleasantly surprised by the overall positive impact it had on his health.

Fetterman described how the medication helped alleviate aches, pains, and stiffness, making him feel physically younger and more optimistic. In addition to these benefits, he also experienced significant weight loss. GLP-1 drugs like Mounjaro have been linked to various health benefits beyond lowering blood sugar, including improved heart health, neurological function, and metabolic health.

Eli Lilly, the maker of Mounjaro, also offers another version of the drug called Zepbound, which is approved for weight loss, chronic weight management, and sleep apnea. Other GLP-1 medications such as Ozempic, Wegovy, Victoza, and Saxenda are made by Novo Nordisk.

Fetterman emphasized the need for expanded access to these medications, which can cost up to $1,000 out of pocket if not covered by insurance. He called for Medicare and Medicaid to cover these drugs more broadly, highlighting their potential to improve the health and quality of life for millions of Americans.

While Fetterman acknowledged the importance of diet and lifestyle changes in improving health, he stressed that medication can be a crucial first step for individuals dealing with serious health issues. He expressed his desire to ensure that anyone who could benefit from these medications has access to them.

Health experts, including Dr. Marc Siegel and Dr. Brett Osborn, underscored the importance of GLP-1 drugs like Mounjaro in treating conditions like type 2 diabetes and obesity. They noted the potential benefits of these medications for heart health, lipid profiles, and cognitive function.

Despite the recent announcement that Medicare and Medicaid would not cover these medications, experts like Osborn believe that this decision is a negotiating tactic to lower drug prices. They remain hopeful that access to these life-changing medications will be expanded in the future.

In conclusion, the positive impact of GLP-1 drugs like Mounjaro on individuals like Sen. Fetterman underscores the importance of ensuring widespread access to these medications. By prioritizing the health and well-being of Americans, policymakers and healthcare providers can help improve outcomes for those struggling with chronic health conditions.